Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/122567
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Muñoz López, Laura | - |
dc.contributor.author | Gonzalez, Lucía | - |
dc.contributor.author | Soldevila, Laura | - |
dc.contributor.author | Dorca i Sargatal, Jordi | - |
dc.contributor.author | Alcaide Fernández de Vega, Fernando | - |
dc.contributor.author | Santín Cerezales, Miguel | - |
dc.date.accessioned | 2018-05-25T07:17:19Z | - |
dc.date.available | 2018-05-25T07:17:19Z | - |
dc.date.issued | 2017-08-30 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/122567 | - |
dc.description.abstract | Objective To assess the utility of QuantiFERON®-TB Gold In-tube (QFT-GIT) for targeting preventive therapy in BCG-vaccinated contacts of tuberculosis (TB), based on its high specificity and negative predictive value for development of TB. Methods We compared two screening strategies for TB contact tracing in two consecutive periods: the tuberculin skin test (TST) period, when all contacts were screened with the TST alone; and the QFT-GIT period, when BCG-vaccinated contacts underwent TST and QFT-GIT. Diagnosis of TB infection among BCG-vaccinated contacts relied on TST ≥5 mm in the TST period, while in the QFT-GIT period either a positive QFT-GIT or a TST ≥15 mm was required. Measurements and main results Six hundred and sixty-one contacts were compared. In the QFT-GIT period there was a reduction in diagnoses of TB infection (77.4% vs. 51.2%; p <0.01) and preventive therapy prescribed (62.1% vs. 48.2%; p = 0.02) among the 290 BCG-vaccinated contacts. After a median follow-up of 5 years, cumulative incidences of TB were 0.62 and 0.29 in the TST and QFT-GIT periods respectively (p = 0.59). Conclusions In BCG-vaccinated TB contacts, the addition of QFT-GIT safely reduced TB diagnosis and treatment rates without increasing the risk of subsequent active TB. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0183258 | - |
dc.relation.ispartof | PLoS One, 2017, vol. 12, num. 8, p. e0183258 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0183258 | - |
dc.rights | cc-by (c) Muñoz, Laura et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Tuberculosi | - |
dc.subject.classification | Vacuna BCG | - |
dc.subject.classification | Estudi de casos | - |
dc.subject.other | Tuberculosis | - |
dc.subject.other | BCG vaccine | - |
dc.subject.other | Case studies | - |
dc.title | QuantiFERON®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 674008 | - |
dc.date.updated | 2018-05-25T07:17:20Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28854216 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
674008.pdf | 1.17 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License